ArticleMolecular pharmaceutics2018
An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules.
Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 52 citations in OpenAlex.
- Tubulin inhibitors: an insight into new strategies to combat leukemia.Future medicinal chemistry · 2025Review
- Structure-Activity Relationship Study of (ACS pharmacology & translational science · 2024Article
- Synthesis, andCurrent computer-aided drug design · 2024Article
- Design and Synthesis of Novel α-Methylchalcone Derivatives, Anti-Cervical Cancer Activity, and Reversal of Drug Resistance in HeLa/DDP Cells.Molecules (Basel, Switzerland) · 2023Article
- A Facile Synthesis and Molecular Characterization of Certain New Anti-Proliferative Indole-Based Chemical Entities.International journal of molecular sciences · 2023Article
- A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growthActa pharmaceutica Sinica. B · 2022Article
- Target-based anticancer indole derivatives and insight into structure‒activity relationship: A mechanistic review update (2018-2021).Acta pharmaceutica Sinica. B · 2022Review
- A novel anti-lung cancer agent inhibits proliferation and epithelial-mesenchymal transition.The Journal of international medical research · 2022Article
- Chalcone Derivatives: Role in Anticancer Therapy.Biomolecules · 2021Review
- The Newly Synthetized Chalcone L1 Is Involved in the Cell Growth Inhibition, Induction of Apoptosis and Suppression of Epithelial-to-Mesenchymal Transition of HeLa Cells.Molecules (Basel, Switzerland) · 2021Article
- Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.Molecules (Basel, Switzerland) · 2020Review
- Antiproliferative Effect of Acridine Chalcone Is Mediated by Induction of Oxidative Stress.Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Multidrug resistance and toxic side effects are the major challenges in cancer treatment with microtubule-targeting agents (MTAs), and thus, there is an urgent clinical need for new therapies. Chalcone, a common simple scaffold found in many natural products, is widely used as a privileged structure in medicinal chemistry. We have previously validated tubulin as the anticancer target for chalcone derivatives. In this study, an α-methyl-substituted indole-chalcone (FC77) was synthesized and found to exhibit an excellent cytotoxicity against the NCI-60 cell lines (average concentration causing 50% growth inhibition = 6 nM). More importantly, several multidrug-resistant cancer cell lines showed no resistance to FC77, and the compound demonstrated good selective toxicity against cancer cells versus normal CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.